Peregrine Pharmaceuticals has announced results from its randomized phase II trial, which is designed to determine overall response rate of carboplatin and paclitaxel with or without bavituximab in 86 patients with front-line, Stage IIIb and Stage IV non-small cell lung cancer.

Circassia, a specialty biopharmaceutical company, has announced positive results from Phase II clinical trial of ragweed allergy therapy.

PhaseBio Pharmaceuticals, a biotechnology company, has initiated Phase I clinical study with its novel compound, Vasomera (PB1046), in patients with Stage 1 and 2 essential hypertension.

TxCell SA, a biotechnology company, has announced positive immuno-monitoring results of the Phase I/II study in Crohn's disease with Ovasave.

Galena Biopharma has initiated Phase III trial for NeuVax (E75 peptide plus GM-CSF) vaccine in HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence.

Genta's Tesetaxel has demonstrated efficacy in the Phase 2b, confirmatory clinical trial, designed to evaluate the drug in patients with advanced gastric cancer.

Sanofi and Regeneron Pharmaceuticals, Inc. announced positive preliminary results from the Phase 2 study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C) were treated with REGN727/SAR236553.

TxCell SA, a biotechnology company developing Treg cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high unmet medical needs, announces today the presentation of final positive results of the phase I/II study in Crohn’s disease (CATS-1) with its leading product candidate, OvaSave(R). The results of this study, performed on 20 patients, were announced at the United European Gastroenterology Week (UEGW) in Stockholm, held October 22 to 26.

AstraZeneca and Forest Laboratories, Inc. announced today that ceftazidime/avibactam (CAZ-AVI) will enter phase III trials to investigate efficacy in treating hospitalised patients with serious Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI combines a broad-spectrum cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam, formerly NXL104) to overcome antibiotic-resistance and treat the increasing number of infections resistant to existing therapies.

First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.